OSI Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on Tuesday, February 5, 2008
OSI Pharmaceuticals, Inc. announced today that Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals, will present at the Merrill Lynch Conference in New York, NY on Tuesday, February 5, 2008 at 8:00am (Eastern Standard Time). Dr. Goddard will provide an overview on the Company's product portfolio and business developments.
The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until February 19, 2008.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity.
The Company's oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care.
OSI's diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world.
For additional information about OSI, please visit http://www.osip.com.
Source : www.ad-hoc-news.de
The presentation will be webcast live and may be accessed by visiting OSI's website at www.osip.com. A replay of the webcast will also be available on the Company's website until February 19, 2008.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing lives" by discovering, developing and commercializing high-quality and novel pharmaceutical products designed to extend life and/or improve the quality of life for patients with cancer and diabetes/obesity.
The Company's oncology programs are focused on developing molecular targeted therapies designed to change the paradigm of cancer care.
OSI's diabetes/obesity efforts are committed to the generation of novel, targeted therapies for the treatment of type 2 diabetes and obesity. OSI's flagship product, Tarceva® (erlotinib), is the first drug discovered and developed by OSI to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings. OSI markets Tarceva through partnerships with Genentech, Inc. in the United States and with Roche throughout the rest of the world.
For additional information about OSI, please visit http://www.osip.com.
Source : www.ad-hoc-news.de
Posts
Post a Comment